Myelodysplastic syndromes: therapeutic problems and decisions (review)

Myelodysplastic syndromes: therapeutic problems and decisions (review)

Show other versions (1)

Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal disorders of myeloid hematopoietic stem cells characterized by an ineffective hematopoiesis associated with cytopenias, morphologic dysplasia and a progression to acute myeloid leukemia. The only potentially curative MDS treatment i...

Full description

Bibliographic Details
Main Authors:	S. V. Semochkin, T. N. Tolstykh, A. G. Rumyantsev
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Онкогематология
Subjects:	myelodysplastic syndromes hypomethylating agents lenalidomide azacitidine decytabine
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/63

Similar Items

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01)

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure
by: Abigail Belasen, et al.
Published: (2020-07-01)

Myelodysplastic syndrome from theoretical review to clinical application view
by: Amrallah A. Mohammad
Published: (2018-12-01)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
by: Sara Mongiorgi, et al.
Published: (2023-02-01)

Myelodysplastic syndromes: Where do we stand?
by: Nitin Sood, et al.
Published: (2016-01-01)

Long-term hematologic response after azacitidine treatment in a lower-risk myelodysplastic syndrome patient: A case report
by: Konstantinos Loukidis, et al.
Published: (2024-01-01)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
by: Josephine Lucero, et al.
Published: (2023-06-01)

New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome
by: E. V. Morozova, et al.
Published: (2022-11-01)

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
by: Jonathan Pan, et al.
Published: (2020-10-01)

A Case of Organizing Pneumonia Following Azacitidine Treatment for Myelodysplastic Syndrome
by: Kelly Ann Hutchinson, et al.
Published: (2023-05-01)

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
by: Francesco D’Alò, et al.
Published: (2021-04-01)

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
by: Paul Lee, et al.
Published: (2021-09-01)

Therapeutic Options in Myelodysplastic Syndromes: Established and Emerging Therapies
by: Nina Kim, et al.
Published: (2018-08-01)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
by: Xin Wang, et al.
Published: (2024-12-01)

Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge
by: Francesco Pisani, et al.
Published: (2014-04-01)

An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum
by: Esra Turan Erkek, et al.
Published: (2016-02-01)

Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
by: Smith Kungwankiattichai, et al.
Published: (2022-02-01)

Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes
by: Moreno Vanegas Y, et al.
Published: (2022-12-01)

Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine
by: Carlo Pescia, et al.
Published: (2021-10-01)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
by: Jehad Almasri, et al.
Published: (2018-09-01)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
by: Hui Liu, et al.
Published: (2023-07-01)

Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis
by: Xinhui Zheng, et al.
Published: (2022-06-01)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
by: De‐hong Wu, et al.
Published: (2020-01-01)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
by: Wang Eunice S, et al.
Published: (2012-11-01)

Epigenetic Silencing of <i>PTEN</i> and Epi-Transcriptional Silencing of <i>MDM2</i> Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents
by: Paul Lee, et al.
Published: (2022-05-01)

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine
by: Shinichi Ogawa, et al.
Published: (2024-01-01)

The mesenchymal compartment in myelodysplastic syndrome: Its role in the pathogenesis of the disorder and its therapeutic targeting
by: Charalampos G. Pontikoglou, et al.
Published: (2023-01-01)

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
by: Eri Takada, et al.
Published: (2024-02-01)

Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience
by: İbrahim Ethem Pınar, et al.
Published: (2021-03-01)

Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform
by: Paul Lee, et al.
Published: (2022-04-01)

Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach
by: Ana María Hurtado López, et al.
Published: (2020-01-01)

The Impact of the Epigenetic Cancer Drug Azacitidine on Host Immunity: The Role of Myelosuppression, Iron Overload and <i>tp53</i> Mutations in a Zebrafish Model
by: Shu-Ching Wang, et al.
Published: (2019-09-01)

Azacitidine Omega-3 Self-Assemblies: Synthesis, Characterization, and Potent Applications for Myelodysplastic Syndromes
by: Milad Baroud, et al.
Published: (2021-12-01)

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
by: António Almeida, et al.
Published: (2017-01-01)

Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis
by: Jun Li, et al.
Published: (2022-12-01)

The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis
by: Yufeng Du, et al.
Published: (2023-12-01)

Immunemodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report
by: Kentaro Serizawa, et al.
Published: (2018-06-01)

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
by: Pedro Marques Ramos, et al.
Published: (2023-08-01)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
by: Marion Divoux, et al.
Published: (2020-09-01)